332 related articles for article (PubMed ID: 23589556)
1. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
3. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
4. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G; Bardou VJ; Clark GM; Elledge RM
Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
[TBL] [Abstract][Full Text] [Related]
5. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Metzger Filho O; Giobbie-Hurder A; Mallon E; Gusterson B; Viale G; Winer EP; Thürlimann B; Gelber RD; Colleoni M; Ejlertsen B; Debled M; Price KN; Regan MM; Coates AS; Goldhirsch A
J Clin Oncol; 2015 Sep; 33(25):2772-9. PubMed ID: 26215945
[TBL] [Abstract][Full Text] [Related]
6. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
7. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
10. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
[TBL] [Abstract][Full Text] [Related]
11. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
13. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
16. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
[TBL] [Abstract][Full Text] [Related]
17. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
18. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
19. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas.
Asch-Kendrick RJ; Samols MA; Lilo MT; Subhawong AP; Sharma R; Illei PB; Argani P; Cimino-Mathews A
J Clin Pathol; 2014 Sep; 67(9):768-71. PubMed ID: 24996432
[TBL] [Abstract][Full Text] [Related]
20. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
